keyboard_arrow_up

Eastern Equine Encephalitis Pipeline and Market Review, H2 2015

Eastern Equine Encephalitis - Pipeline Review, H2 2015 Report reviews key players involved in the therapeutic development for Eastern Equine Encephalitis and special features on late-stage and discontinued projects.

This report provides comprehensive information on the therapeutic development for Eastern Equine Encephalitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Companies mentioned in this report are AlphaVax, Inc., AltraVax Inc., EpiVax, Inc., Profectus BioSciences, Inc.

Get a copy of this report http://bit.ly/1Msy95P . This is a premium report price at US$2000 for a single user PDF license

Scope

·         The report provides a snapshot of the global therapeutic landscape of Eastern Equine Encephalitis

·         The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

·         The report reviews key players involved in the therapeutics development for Eastern Equine Encephalitis and enlists all their major and minor projects

·         The report summarizes all the dormant and discontinued pipeline projects

·         A review of the Eastern Equine Encephalitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

·         Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

·         A detailed assessment of monotherapy and combination therapy pipeline projects

·         Coverage of the Eastern Equine Encephalitis pipeline on the basis of target, MoA, route of administration and molecule type

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.